Multiomic Health

MultiOmic Health (Multiomic Health Limited) is a London-based, AI-enabled drug discovery company applying multi-omics analysis and computational systems biology to age-related chronic multifactorial diseases. Its focus is the cardio-renal-metabolic (CRM) disease continuum — the cluster historically described as metabolic syndrome (insulin resistance, hypertension, dyslipidemia, abdominal adiposity) and its downstream conditions including type 2 diabetes, atherosclerotic cardiovascular disease, non-alcoholic fatty liver disease and chronic kidney disease. The company's stated premise is that these conditions are treated with imprecise, one-size-fits-all medicines and that few endotypes in this space can be defined by a single genotype, so patient sub-populations must instead be identified by integrating multiple omics modalities with longitudinal clinical phenotyping.

The company's first platform use case is chronic kidney disease, with near-term work on precision therapeutics for CKD and planned expansion into cardiorenal conditions and diabetic complications. Outputs are framed as two impact routes: renal endotypes and patient-stratifying models implemented as diagnostic products (SaMD, IVD), and patient-stratified renal drug targets paired with companion diagnostics. Its pipeline consists of active programs advancing towards preclinical candidates, all targeting dysfunctional pathways implicated in kidney inflammation and fibrosis across multiple aetiologies. The company also states it has begun building a global CRM patient registry intended to capture over 100,000 patients by 2028.

The team is led by co-founder and CEO Robert Thong, with co-founder and non-executive director Alasdair Thong, and includes clinical, scientific, technology, translational science, computational biology and business development staff drawn from Novartis, ICON, GSK, LEO Pharma, AstraZeneca and academic institutions, plus scientific advisors with backgrounds at Roche, Bayer and other biopharma organisations. Investor directors from MMC Ventures and Hoxton Ventures sit on the board.

Founding story

MultiOmic was founded in 2021, motivated by falling costs of generating omics data and advances in artificial intelligence, to apply precision medicine to metabolic syndrome-derived conditions, an area where precision approaches had made far less progress than in oncology because few simple genetic or protein markers define responder sub-groups. The company began operations in May 2021 and is registered in the UK as Multiomic Health Limited (company #13246608).

Business model

The company originates novel precision therapeutic concepts and diagnostic assets from its platform and commercialises them through partnerships with established biopharma companies. It sources de-identified patient data and biological samples through partnerships with healthcare providers, research institutions, biobanks and healthtech companies, and uses a network of omics technology and diagnostic laboratory service providers to generate molecular data.

Commercialisation is stated to occur via partnerships with established biopharma companies for precision therapeutic concepts, alongside potential diagnostic products (software as a medical device, in vitro diagnostics and companion diagnostics) derived from its endotyping and patient-stratifying models.

Traction

By May 2023 the company had raised $8.6 million in total funding and stated it would use the latest round to demonstrate proof of concept for MOHSAIC in diabetic kidney disease. It has an active program pipeline advancing towards preclinical candidates targeting kidney inflammation and fibrosis pathways, a partnership with Mesh Bio, and a stated plan to build a global CRM patient registry capturing over 100,000 patients by 2028.

Latest developments

The company's current website describes an active pipeline of programs advancing towards preclinical candidates, all targeting dysfunctional pathways implicated in kidney inflammation and fibrosis, and frames its work around the cardio-renal-metabolic disease continuum with chronic kidney disease as the first platform use case, plus a global CRM patient registry targeting over 100,000 patients by 2028.